Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Samuel Michael Owens
Univ of Arkansas for Med Scis, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
InterveXion Therapeutics,LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The investigator has equity and proprietary interests in InterveXion Therapeutics, LLC, a private company developed for treatment of human diseases, including drug abuse, and is involved in research that ths the potential to affect this company.
Antibody Gene Therapy for Methamphetamine Abuse
This research aims to develop groundbreaking medical therapy for significantly improving treatment of methamphetamine abuse. Through the integration of advanced antibody engineering and gene therapy technology, innovative long-acting antibody-based medicine will be created to both protect patients from relapse to methamphetamine use and to minimize treatment failures associated with long-term patient compliance.
Filed on May 07, 2015.
Tell us what you know about Samuel Michael Owens's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Samuel Michael Owens”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Samuel Michael Owens | Intervexion Therapeutics, Llc | Conflict of Interest | InterveXion Therapeutics, LLC | $0 - $4,999 |
| Samuel Michael Owens | Intervexion Therapeutics, Llc | Conflict of Interest | InterveXion Therapeutics, LLC | $0 - $4,999 |
| Samuel Michael Owens | Intervexion Therapeutics, Llc | Conflict of Interest | InterveXion Therapeutics, LLC | $0 - $4,999 |
| Samuel Michael Owens | Intervexion Therapeutics, Llc | Conflict of Interest | InterveXion Therapeutics, LLC | $0 - $4,999 |
| Samuel Michael Owens | Intervexion Therapeutics, Llc | Conflict of Interest | InterveXion Therapeutics, LLC | $0 - $4,999 |
| Samuel Michael Owens | Intervexion Therapeutics, Llc | Conflict of Interest | InterveXion Therapeutics, LLC | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.